Notable Labs

Notable Labs ROE

The Return on Equity (ROE) of Notable Labs (NTBLQ) as of Nov 11, 2026 is -74.53 %. In the previous year, Return on Equity (ROE) was -143.88 % — a change of -48.20% (higher).

ROE

-74.53 %

YoY

-48.20%

Last updated:

In 2023, Notable Labs's return on equity (ROE) was -74.53 %, a -48.20% increase from the -143.88 % ROE in the previous year.

The Notable Labs ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2016
-37.74 USD
Jan 1, 2017
-18.14 USD
Jan 1, 2018
-38.61 USD
Jan 1, 2019
-53.86 USD
Jan 1, 2020
-78.36 USD
Jan 1, 2021
-57.34 USD
Jan 1, 2022
-143.88 USD
Jan 1, 2023
-74.53 USD
The Notable Labs ROE history
YEARROEYoY
-74.53 %-48.20%
-143.88 %+150.92%
-57.34 %-26.83%
-78.36 %+45.50%
-53.86 %+39.48%
-38.61 %+112.87%
-18.14 %-51.93%
-37.74 %-11.27%
-42.53 %-14.25%
-49.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

ROE Details

Decoding Notable Labs's Return on Equity (ROE)

Notable Labs's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Notable Labs's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Notable Labs's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Notable Labs’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Notable Labs stock

Return on Equity (ROE) of Notable Labs is -74.53 % in 2023.

Return on Equity (ROE) of Notable Labs changed from -143.88 % to -74.53 %, representing a -48.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Notable Labs since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Notable Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Notable Labs

All Key Metrics — Notable Labs